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~,-Antit~psin; (a,-AT) produced by various human carcinoma (non-hepatoma) cell lines were analyzed. Ftve out of eight ceil lines secreted 
detectable amounts of a,-AT into the ~onditloned media. All were aden~arcinoma cell lines. The tumor cell-derived a,-ATs had higher molecular 
weights (MW) than the normal plasma form. Most of this difference was an overall reflection of altered ~-~ycosylation. As judged by binding 
of iectins, the glycosyiation had shifted towards higher levels of triantennary oligosaccharides and higher levels of fucosylation. The condittoned 
media also contained lower MW CX,-AT species, possibly, proteolytically cleaved forms. 
a,-Antitrypsin; Adenocarcinoma cell; Glycosylation 
1. INTRODUCTION 
~,-Antitrypsin (q-AT) is a glycoprotein and a major 
component of serum proteinase inhibitors. The mature 
protein is a single polypeptide containing one cysteine 
residue, no disulphide bridges. and three carbohydrate 
side chains [l]. It is classically considered to be synthe- 
sized by liver cells and, to a lesser extent, by macro- 
phages. 
Increased q-AT in sera or tumor tissue from various 
cancer patients have been described [2,3]. We have pre- 
viously shown that cultured human colorectal 
adenocarcinoma cell lines produce functionally active 
q-AT [4], and patients with immunohisto~hemically q- 
AT- positive colorectal carcinomas have a worse prog- 
nosis than those with negative ones [5]. Similar results 
were obtained in patients with gastric carcinomas and 
lung adenocarcinomas [6,7]. A human breast carcinoma 
cell line, MCF-7, secretes an q-AT-like 61 kDa protein 
which may act as a positive growth factor under the 
stimulation of estradiol [8]. These lines of evidence sug- 
gest that the tumor cell-derived @,-AT may play a signif- 
icant role in tumor biology. However, little is known 
about the properties of carcinoma (except for 
hepatoma) cell-derived q-AT. In the present paper we 
describe some of the properties of q-AT secreted by 
various human adenocarcinoma cell lines. 
RCM-3, and CoCM-1; a lung adenocarcmoma cell line. LC-Z/ad; a 
squamous cell carcinoma cell line, LC-l/sq; a renal cell carcinoma cell 
line, MRT-I; and a urinary bladder transittonal cell carcmoma cell 
line, UMK-I; were used. All lines have been established in our labora- 
tory [4.9,10], and were grown m a mixture of RPM1 1640 and Ham’s 
F-12 (l:lf supplements with 10% fetal bovine serum (FBS) (G&o, 
Gland Island, NY, USA) and kept at 37°C in a humidified atmosphere 
containing 5% CO,. To collect serum-free condnioned medium 
(SFCM), confluent cells were rinsed 3 times with serum-free medmm 
and cultured in the serum-free medium. SFCM was harvested and 
cultures were re-fed every day for 4 days. The media collected on the 
first day were discarded while subsequent harvests were collected, 
centrifuged (2,000 x g. 20 min) and stored at -40°C. 
2.2. Column chromatography 
High-performance liquid chromatography (HPLC) was performed 
with Pharmacia’s FPLC system (Uppsala, Sweden). Concanavalin A 
(Con A) affinity HPLC fractionation was performed on a LA-Con A 
column (0.45 x 15 cm, Seikagakukogyo. Tokyo. Japan) equilibrated 
with 50 mM Trts-HC1 (pH 7.2), 200 mM NaCl, 1 mM Mn Cl?, 1 mM 
CaCI,. Bound protein was eluted with a linear gradient of O--l00 mM 
ff-methyl-o-glucoside in the initial buffer. Partial purification of CZ,-AT 
from SFCM was as described previously [4]. Darura srramonmm ag- 
glutinin (DSA) affinity chromatography was performed on a DSA- 
agarose column (1 ml, Seikagakukogyo) equilibrated with 50 mM 
phosphate buffer (pH 7.0) 150 mM NaCl, 0.01% NaN,. Lotus 
tetragonolobus agglutmin (LTA), affinity chromatography was per- 
formed on a LTA-agarose column (1 ml, Seikagakukogyo) equih- 
brated with the same buffer as DSA-agarose. Sample was applied on 
the lectin-agarose column and re-circulated through the column for 
30 min at 4°C. After washmg the columns wrth the buffer, bound 
proterns were eluted with a stepwise gradient of 2 ml each of 0.5%, I%, 
and 2% of a mixture of chitooligosaccharides for the DSA column, 
and with 3 ml each of 20 mM and 50 mM a-L-fucose for the LTA 
column. 
2. MATERIALS AND METHODS 
2. I. Cell culture 
2.3. Con A af%ify electrophoresis 
Four human colorectal adenocarcmoma cell lines, RCM-1. RCM-2, 
Correspondence address: M. Koono, Second Department of Pathol- 
ogy, Miyazaki Medical College, 5200 Kihara, Kiyotake. Miyazaki 
889-16, Japan. Fax: (81) (985) 856 003. 
Con A affinity electrophoresis was carried out at 15°C. using 0.6 
mg Con A (Stgma, St. Louis, MO, USA) in a 0.9% agarose gel (LE 
agarose. FMC BioProducts, Rockland, MO, USA). Barbital buffer 
(pH 8 6). ionic strength 0.05, was used. After the electrophoresis (4.5 
V/cm, 6h) the proteins were transfered onto a mtrocellulose paper 
(0.45 pm, Schleichen and Schuell, Dassel, Germany) by the capillary 
method overnight, After transfer the paper was blocked with 1.25% 
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non-fat milk protein m 50 mM Trts-Hfl (pH 7.6). 200 mM N&l 
(TBS) for 3 h at room temperature. followed by brief washing in TBS, 
0.05% Tween 20. Then the paper was incubated m 0.5% rabbit anti- 
human a,-AT IgG (Dakopatts, Glostrup, Denmark) m TBS. 3% FBS, 
SO mM cc-methyl mannoside (a-MM) for 2 h. After 3 washes in TBS. 
0 05% Tween 20, the paper was Incubated in peroxidase-conjugated 
secondary antibody (0.2% swine an&rabbit immunoglobulin IgG in 
TBS. 1% FBS, 50 mM a-MM for 1 h followed by 3 washes m TBS 
4-Chloro-l-naphthol was used as the colour reagent. Bovine cr,-AT 
did not cross-react under these conditions. 
SDS-PAGE was performed under reducmg conditions using a 10% 
separatmg el. After electrophoresis, the protems were transfered elec- 
trophoretlcally onto nltr~ellulose paper [ll]. Then, the paper was 
processed for immunostaining using rabbit anti-human a,-AT IgG as 
described above. GI-MM was removed from the buffer for this case. 
Y&well mtcrotiter plates were coated with sheep anti-human a,-AT 
IgG (40 pug/ml. Serotec. UK) in 10 mM sodium carbonate buffer (pH 
9.6). After washing with phosphate-buffered saline (pH 7.2), 0.1% 
Tween 20 (PBS-Tween). the wells were blocked with PBS, 3% bovme 
serum albumm (Fraction V. Boehrmger-Mannhelm. Germany). for 1 
h at 37°C Then samples (200 ,&/well, diluted with PBS-Tween) were 
appiied and incubated for 1 h at 37°C followed by 3 washes with 
PBS-Tween. Subsequently 200,& of peroxidase-conjugated secondary 
antibody (sheep anti-human a,-AT IgG. 10 pg/mI, Serotec) in PBS- 
Tween. 1% FBS, was applied, and incubated for 1 h at 37°C. After 
3 washes with PBS. the colour reaction was done by using 0.5 mgiml 
O-phenylenediamme, sodmm phosphate buffer (0 1 M, adjusted to pH 
5.0 with 0.1 M citric acid) Medium contammg 10% PBS. or serum- 
free medium. was used as a control. In any case the samples and 
standards were dtluted with PBS-Tween. 3% FBS. Bovme a,-AT. 
which was present m FBS. dtd not cross-react m this system. 
XGlycostdase F (Boehrmger-Mannhetm) treatment was done ac- 
cordmg to the manufacturer’s mstructtons. Briefly, samples were 
boiled for 3 min rn the presence of 1% SDS. then incubated overmght, 
at 37°C m 50 mM phosphate buffer (pH 7.X). l%~-mercaptoethanol. 
0.5% Nonidet P-40. 20 mM EDTA, with or without 10 U/ml A’- 
glycosidase F. After treatment. the samples were processed for West- 
ern blotting as described above. 
The inhibition assay for TPCK-treated trypsin (Stgma) was de- 
scribed previously 141: Bz-t,-Arg-pNA (Sigma) was used as a substrate. 
Zymography was used for detecting a,-AT-degradmg protemase 




Five out of eight cell lines secreted protein im- 
munoreactive with antibodies to human a,-AT: all were 
adenocarcinoma cell lines. Apparently the amount of 
q-AT in each conditioned medium was much higher in 
LC-2/ad, RCM-1 and MRT-I than the other cell lines 
(Table 1). Treatment of RCM-I with lO,&ml cyclohex- 
amide for 24 h inhibited the secretion of q-AT almost 
completely (94%). Western blot analysis using a rabbit 
anti-human a,-AT IgG identified a broad protein band 
of 53-70 kDa and an intense band of 59-62 kDa (Fig. 
1). Immunoadsorption of the antibody with pure ol,-AT 
eliminated these bands (data not shown). An additional 
weak band of approximately 90 kDa was occasionally 
seen in the case of RCM-1. The size of the protein is 
apparently larger than normal human plasma a,-AT 
which migrated to a position of 56 kDa in our gel. Since 
the higher molecular weight (MW) and the broad band 
of the tumor cell-derived q-AT may be an overall re- 
flection of altered glycosylation, we examined the affin- 
Table I 
Secretion of a,-AT by carcmoma cell lines 
Cell line Passage 
numbers 
Type Origin a,-AT 
@ml/24 h rig/l Oh cells124 h
RCM-I 44 Adenocarcinoma Rectum 20.5 13.0 
RCM-1 + cyclohexamide 10 &ml 1.2 0.6 
RCM-1 102 124.0 46.5 
RCM-2 60 Adenocarclnoma Rectum < 1.0 
RCM-3 58 Adenocarcinoma Rect urn 5.2 9.8 
CoCM-I 37 Adenocarcinoma Colon 4.4 1.2 
MRT-1 90 Renal cell carcinoma Kidney 25 5 42 4 
(adenocarcinoma) 
LC-Z/ad 54 Adenocarcinoma Lung 4160 693.3 
LC-llsq 72 Squamous cell carcinoma Lung < 1.0 
UMK-1 42 Transitional cell carcinoma Urmary bladder <lo 
UMK-1 115 < 1.0 
ff,-AT antigen levels were determmed by EIA using sub- or confluent cultured cells in 25 cm2 flask with 5 ml growth medium for 24 h. 
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Fig. 1. Western blot analysis of q-AT derived from RCM-1 (a) and 
LC-Z/ad (b). Lanes al-3, SFCMs of RCM-1 of 102nd, 84th. 42nd 
passage, respectively. 30 ,ul each of 50 x concentrated SFCM was 
applied: lane bl: partially purified LC-Z/ad q-AT. 0.6pg; lanes a4.b2, 
normal plasma a,-AT (1 and 0.4 ,ug, respectively); lanes aS.b3, pres- 
tained MW marker. 
ity of the tumor q-AT to various lectins and the effects 
of N-glycosidase F treatment. 
3.2. Con A af$inity 
When partially purified RCM-l-derived cl,-AT was 
analyzed with Con A HPLC, only 10% of the activities 
were retained in the column, whereas 78% of the activ- 
ities of commercially obtained human plasma cl,-AT 
were retained. Con A affinity electrophoresis followed 
by immunoblotting using a rabbit anti-human cr,-AT 
IgG also revealed decreased affinity of LC-2/ad-derived 
ol,-AT to Con A (Fig. 2). A similar result was obtained 
in the case of RCM-1 (data not shown). Under these 
electrophoretic conditions, the tumor a,-AT showed a 
considerable broad band when compared with the 
plasma q-AT. Although the electrophoresis pattern of 
the plasma q-AT was significantly affected by Con A 
resulting in three main bands (i.e. strong, moderate, and 
weak or no affinity to Con A), the pattern of the tumor 
q-AT was only slightly affected by Con A and most of 
the protein show weak or no affinity to Con A. 
3.3. DSA and LTA affinity 
Results of DSA-agarose column chromatography 
are shown in Fig. 3. Both RCM- 1, and LC-2/ad-derived 
a,-AT contain DSA-bound fractions. About 40% and 
12% of the RCM-1 and LC-2/ad-derived q-AT, respec- 
tively, bound to the column. In contrast, only 2% of the 
normal q-AT bound to the column. When analyzed 
with LTA-agarose column chromatography, part of the 
RCM-1 derived q-AT was retained in the column and 
eluted with L-fucose. Most of the plasma q-AT was not 
retained in the column. Although part of the LC-2/ad- 
ConA, 
t-1 I2 ;, 
(+I 
front 
Fig. 2. Con A affinity electrophoresis of q-AT. Lanes 1.4, 0 3 pg of 
normal plasma a,-AT; lanes 2,5. 10 ~1 (50 x concentrated) of SFCM 
of LC-Z/ad; lane 3,5 ~1 of FBS. After electrophoresis. the proteins were 
transfered to nitrocellulose paper and immunostamed with anti- 
human q-AT IgG. The electrophoretic pattern of normal a,-AT was 
significantly altered by Con A showing 3 main bands (arrow head). 
derived q-AT was also retained in the column, the 
amount was much lower than that of RCM-l-derived 
a,-AT (Fig. 4). Of particular interest is the observation 
that the molecular sizes of the DSA- and LTA-bound 
tumor cx,-AT were clearly larger than the plasma q-AT, 
and even larger than the unbound tumor cr,-AT. 
3.4. Effects of N-glycosidase F treatment 
Fig. 5 shows the results of N-glycosidase F treatment. 
Both plasma and the tumor a,-ATs were totally sensi- 
tive to N-glycosidase F. After treatment, plasma cl,-AT 
decreased its size from 56 kDa to 44 kDa. Treatment of 
the tumor a,-AT resulted in 51, 44, 42, 39. and 37 kDa 
products for RCM-1; 44, 42, 39, and 37 kDa products 
for LC-Z/ad; and a 44 kDa product for MRT-1. In any 
case the main products were of the same MW in size, 
i.e. 44 kDa. This result, together with the results of 
lectin affinity, clearly indicated that the higher MW 
species of tumor q-AT were derived mostly from ab- 













Fig. 3. Western blot analysis of a,-AT fractionated with DSA affinity 
chromatography. (a) SFCM of RCM-1; (b.d) normal plasma a,-AT: 
(c) SFCM of LC-Z/ad. Lane 1, flow through, 3 ml: lane 2, first washing 
with the imtial buffer, 3 ml; lanes 335. elution with 0.5, 1, 2% of a 
mixture of chitoohgosacchandes in the buffer, 2 ml each. 10% of each 
fraction was applied on each lane. 
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Fig. 4. Western blot analysis of a,-AT fractionated wtth LTA affinity 
chromatography (a) SFCM of RCM-1: (b) SFCM of LC-2/ad; (c) 
normal plasma ACE,-AT. Lane 1, flow through, 3 ml; lane 2. first wash 
with the mitral buffer. 3 ml: lane 3.4. fractions eluted wtth 3 ml of 20 
and 50 mM a-L-fucose, respectively. 10% of each unbound fraction or 
30% of each eluted fraction was apphed 
normal glycosylation. Furthermore, the presence of 
varying sizes of polypeptides, mostly smaller than 44 
kDa, might also contribute to formation of the broad 
band seen in Western blot analysis. The 5 1 kDa product 
which is present in the case of RCM-1 may be an a,- 
AT-proteinase complex, since RCM-1 secreted a serine 
proteinase which was sensitive to the endogenous a,-AT 
[13]. The presence of lower MW products in the cases 
of RCM-l- and LC-2/ad-derived a,-AT suggested that 
the conditioned media had a,-AT-degrading activities. 
Results of an a,-AT zymogram of the conditioned 
media support this hypothesis. All media examined con- 
tained a,-AT-degrading activities aside from their size 
and strength (Fig. 6). The main al-AT-degrading activ- 
ity of RCM-1 was larger than 200 kDa. Similar high 
MW proteinase was also detected in gelatin zymogra- 
phy (data not shown) and by gel-filtration chromatog- 
raphy of SFCM of RCM-1 [I 31. 
Fig. 5. Western blot analysis of q-AT after treatment with N-glycosi- 
dase F. SFCMs of (a) MRT-1: (b) RCM-1: (d) LC-2lad; and (c,e) 
normal plasma q-AT. Lane 1, sample without any treatment; lane 2, 
with overnight incubation in the digestion buffer wtthout N-glycosi- 
dase F: lane 3. after N-glycosidase F treatment. 
43 
28 
Fig. 6. q-AT zymography. 45 ,~l of 20 x concentrated SFCM were 
applied on a 10% SDS-polyacrylamide gel containing 0.5 mg/ml a,- 
AT. (Lane 1) LC-‘/ad: (lane 2) RCM-I; (lane 3) MRT-1. In lane 3, 
7.5% gel was used and part of the incorporated a,-AT was also electro- 
phoresed. 
4. DISCUSSION 
There have been a few reports concerning the proper- 
ties of a,-AT derived from hepatoma cells [14] since 
a,-AT is considered to be synthesized mostly by hepato- 
cytes. In this report, we showed that besides hepatoma 
cells, adenocarcinoma cell lines also secrete a,-AT. The 
data presented here provide further evidence for differ- 
ences in the glycosylation of a,-AT between the normal 
plasma form and the adenocarcinoma-derived form. 
According to the Con A and DSA affinity, it seems 
likely that the tumor-derived a,-AT is a mixture of 
heterogeneously glycosylated proteins and that most of 
the proteins have two or three triantennary-type glycans 
[15] or abnormally glycosylated side chains [14], and 
part of the protein may possibly have triantennary oli- 
gosaccharides with C-2, 6-linked structures with or 
without repeating N-acetyllactosamine units [ 161. Fur- 
thermore, the LTA affinity experiments revealed that 
parts of the protein, particularly in the case of RCM-1, 
have higher levels of fucosylation than normal plasma 
a,-AT, since LTA specificity is directed towards fuco- 
syl-o-galactose, fucosyl chitobiose and lacto-l\i- 
fucopentaous bearing Lex‘ [17]. Interestingly, 
Thompson et al. described the presence of LTA-ex- 
tractable fucosylated forms of a,-AT in sera from ovar- 
ian cancer. and that increases in LTA-extractable a,-AT 
are associated with a poor response to chemotherapy 
[18]. Although the source of the LTA-extractable a,-AT 
is uncertain, according to the present study, the tumor 
itself would be one of the sources. Similar changes of 
N-glycosylation pattern, i.e. shifts towards higher levels 
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of triantennary oligosaccharides and higher levels of 
fucosylation, have also been described in cases of tumor 
cell-derived human chorionic gonadotropin [ 193, and 
serum transferin of patients with hepatocellular carci- 
noma [20]. 
The role and significance of the tumor-derived q-AT, 
in particular abnormally glycosylated forms, are not 
known at present. Since a,-AT can inhibit natural killer 
(NK) cell activity [2 I], and Con A non-reactive isoforms 
of a,-AT inhibit the NK activity more efficiently [22], 
the tumor q-AT may modulate the host NK activity in 
favor of the tumor cells. By using purified tumor q-AT, 
further investigations concerning structures with altered 
sugar chains and their effects on tumor-host interac- 
tions would be available. SFCM of tumor cells also 
contained possibly proteolytically cleaved forms of CL,- 
AT, and q-AT-degrading activities, such that the bio- 
logical significance of fragmented q-AT should also be 
considered. For example, proteolytically processed 01,- 
AT can act as a neutrophil chemoattractant [23], and 
the infiltrated neutrophils may enhance tissue destruc- 
tion in the tumor microenvironment. Further character- 
ization of the tumor cell-derived q-AT-degrading activ- 
ities is now underway. 
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